REGENXBIO (RGNX) Competitors

REGENXBIO (NASDAQ:RGNX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.

Does the media refer more to RGNX or ADPT?

In the previous week, REGENXBIO had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 4 mentions for REGENXBIO and 2 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.20 beat REGENXBIO's score of 1.13 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is RGNX or ADPT more profitable?

Adaptive Biotechnologies has a net margin of -100.69% compared to REGENXBIO's net margin of -282.72%. Adaptive Biotechnologies' return on equity of -43.10% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-282.72%	-56.21%	-34.84%
Adaptive Biotechnologies	-100.69%	-43.10%	-23.16%

Which has preferable earnings & valuation, RGNX or ADPT?

Adaptive Biotechnologies has higher revenue and earnings than REGENXBIO. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$112.72M	6.67	-$280.32M	-$6.32	-2.71
Adaptive Biotechnologies	$189.60M	3.87	-$200.19M	-$1.33	-3.81

Which has more volatility & risk, RGNX or ADPT?

REGENXBIO has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Do analysts rate RGNX or ADPT?

REGENXBIO currently has a consensus target price of $35.00, suggesting a potential upside of 104.56%. Adaptive Biotechnologies has a consensus target price of $12.25, suggesting a potential upside of 141.62%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Do institutionals and insiders hold more shares of RGNX or ADPT?

88.8% of REGENXBIO shares are held by institutional investors. Comparatively, 94.3% of Adaptive Biotechnologies shares are held by institutional investors. 13.6% of REGENXBIO shares are held by insiders. Comparatively, 5.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in RGNX or ADPT?

REGENXBIO received 327 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 66.61% of users gave REGENXBIO an outperform vote while only 55.84% of users gave Adaptive Biotechnologies an outperform vote.

Company	Underperform	Outperform
REGENXBIO	Outperform Votes 413 66.61%	Underperform Votes 207 33.39%
Adaptive Biotechnologies	Outperform Votes 86 55.84%	Underperform Votes 68 44.16%

Summary

Adaptive Biotechnologies beats REGENXBIO on 10 of the 18 factors compared between the two stocks.